AstraZeneca PLC's stock rose by 3.00%, reaching a 20-day high, amid positive market conditions with the Nasdaq-100 up 0.69% and the S&P 500 up 0.40%.
The increase in stock price is attributed to AstraZeneca's announcement of successful Phase 3 TULIP-SC trial results for Saphnelo, where 56.2% of patients showed improvement in disease activity, significantly higher than the 37.1% in the placebo group. This success reinforces Saphnelo's unique mechanism in lupus treatment and aligns with AstraZeneca's strategic goal of enhancing lupus care.
The positive trial results not only boost investor confidence but also highlight the global market potential for Saphnelo, which is already approved in over 70 countries. This positions AstraZeneca favorably for future growth opportunities in the healthcare sector.
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 102.75 USD with a low forecast of 95.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast AZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AZN is 102.75 USD with a low forecast of 95.00 USD and a high forecast of 108.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 95.600
Low
95.00
Averages
102.75
High
108.00
Current: 95.600
Low
95.00
Averages
102.75
High
108.00
Citi
Buy
initiated
£17,000
2026-01-27
New
Reason
Citi
Price Target
£17,000
AI Analysis
2026-01-27
New
initiated
Buy
Reason
Citi initiated coverage of AstraZeneca with a Buy rating and 17,000 GBp price target. The firm says the company has the "fastest" mid-term sales and earning growth in the Europe pharma sector. This is driven by AstraZeneca's in-market and pipeline products, the analyst tells investors in a research note.
Deutsche Bank
Emmanuel Papadakis
Sell
maintain
2026-01-16
Reason
Deutsche Bank
Emmanuel Papadakis
Price Target
2026-01-16
maintain
Sell
Reason
Deutsche Bank analyst Emmanuel Papadakis raised the firm's price target on AstraZeneca to 11,000 GBp from 10,500 GBp and keeps a Sell rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for AZN
Unlock Now
Barclays
James Gordon
NULL -> Overweight
upgrade
2026-01-06
Reason
Barclays
James Gordon
Price Target
2026-01-06
upgrade
NULL -> Overweight
Reason
Barclays analyst James Gordon raised the firm's price target on AstraZeneca to 16,500 GBp from 14,000 GBp and keeps an Overweight rating on the shares.
Goldman Sachs
downgrade
2026-01-05
Reason
Goldman Sachs
Price Target
2026-01-05
downgrade
Reason
Goldman Sachs analysts removed AstraZeneca from the firm's European Conviction List as part of its monthly update.
About AZN
AstraZeneca PLC is a United Kingdom-based science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines. The Company operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. It has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The Company distributes its products in over 125 countries.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
